Si-Pei Wu

2.4k total citations · 1 hit paper
23 papers, 1.5k citations indexed

About

Si-Pei Wu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Si-Pei Wu has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in Si-Pei Wu's work include Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Cells and Metastasis (5 papers). Si-Pei Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Cells and Metastasis (5 papers). Si-Pei Wu collaborates with scholars based in China, India and United States. Si-Pei Wu's co-authors include Yi‐Long Wu, Zhong‐Yi Dong, Ri-Qiang Liao, Wen‐Zhao Zhong, Zhi Xie, Hai‐Yan Tu, Jian Su, Xu‐Chao Zhang, Li‐Xu Yan and Jin‐Ji Yang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Si-Pei Wu

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

2016 741 citations Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Si-Pei Wu China	13	941	659	544	386	300	23	1.5k
Lerong Li United States	14	827 0.9×	215 0.3×	699 1.3×	175 0.5×	386 1.3×	21	1.4k
Chit Chow Hong Kong	21	646 0.7×	568 0.9×	534 1.0×	396 1.0×	117 0.4×	53	1.4k
Zhigang Kang United States	11	483 0.5×	303 0.5×	483 0.9×	204 0.5×	173 0.6×	18	1.1k
Steven McCune United States	10	1.1k 1.2×	815 1.2×	330 0.6×	112 0.3×	240 0.8×	19	1.6k
Yien Ning Sophia Wong United Kingdom	8	687 0.7×	350 0.5×	387 0.7×	284 0.7×	325 1.1×	17	1.1k
María Villalba Spain	20	366 0.4×	143 0.2×	407 0.7×	232 0.6×	341 1.1×	35	959
Gunhild Jug Austria	16	255 0.3×	426 0.6×	503 0.9×	174 0.5×	109 0.4×	23	907
Falguni Parikh India	13	747 0.8×	155 0.2×	474 0.9×	327 0.8×	425 1.4×	50	1.3k
Miren Zuazo Spain	17	1.0k 1.1×	195 0.3×	296 0.5×	123 0.3×	760 2.5×	27	1.4k
Hideaki Mitsui Japan	18	320 0.3×	290 0.4×	393 0.7×	206 0.5×	69 0.2×	47	863

Countries citing papers authored by Si-Pei Wu

Since Specialization

Citations

This map shows the geographic impact of Si-Pei Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Si-Pei Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Si-Pei Wu more than expected).

Fields of papers citing papers by Si-Pei Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Si-Pei Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Si-Pei Wu. The network helps show where Si-Pei Wu may publish in the future.

Co-authorship network of co-authors of Si-Pei Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Si-Pei Wu. A scholar is included among the top collaborators of Si-Pei Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Si-Pei Wu. Si-Pei Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Zhihong, et al.. (2022). Prognostic features and comprehensive genomic analysis of NF1 mutations in EGFR mutant lung cancer patients. Cancer Medicine. 12(1). 396–406. 5 indexed citations

Lai, Xiaorong, Fei Xu, Si-Pei Wu, et al.. (2021). Correlation of c-MET expression with clinical characteristics and the prognosis of colorectal cancer. Journal of Gastrointestinal Oncology. 12(5). 2203–2210. 5 indexed citations

Wang, Wenjun, Xiaoqing Liu, Si-Pei Wu, et al.. (2020). Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics. The Journal of Infectious Diseases. 222(9). 1444–1451. 124 indexed citations

Yang, Jing, Si-Pei Wu, Wenjun Wang, et al.. (2020). A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer. Experimental Cell Research. 391(2). 111817–111817. 21 indexed citations

Liu, Si‐Yang Maggie, Zhong‐Yi Dong, Si-Pei Wu, et al.. (2018). Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Lung Cancer. 125. 86–92. 56 indexed citations

Huang, Shu‐Mei, Si-Pei Wu, Ri-Qiang Liao, et al.. (2017). P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 12(1). S961–S962. 1 indexed citations

Wu, Si-Pei, Ri-Qiang Liao, Hai‐Yan Tu, et al.. (2017). Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. Journal of Thoracic Oncology. 13(4). 521–532. 120 indexed citations

Dong, Zhong‐Yi, Wen‐Zhao Zhong, Si‐Yang Maggie Liu, et al.. (2017). MA15.10 Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Journal of Thoracic Oncology. 12(1). S432–S433. 20 indexed citations

Liu, Si‐Yang Maggie, Zhong‐Yi Dong, Si-Pei Wu, et al.. (2017). JCES01.18 Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity. Journal of Thoracic Oncology. 12(1). S237–S237. 1 indexed citations

10.

Huang, Shu‐Mei, Jin‐Ji Yang, Hua‐Jun Chen, et al.. (2017). Epidermal growth factor receptor is associated with the onset of skeletal related events in non-small cell lung cancer. Oncotarget. 8(46). 81369–81376. 4 indexed citations

11.

Xia, Xiaojun, et al.. (2017). Cancer immunotherapy: A need for peripheral immunodynamic monitoring. American Journal of Reproductive Immunology. 79(6). e12793–e12793. 8 indexed citations

12.

Wang, Wenjun, Minzhang Guo, Xiaojun Xia, et al.. (2017). XRRA1 Targets ATM/CHK1/2-Mediated DNA Repair in Colorectal Cancer. BioMed Research International. 2017. 1–11. 14 indexed citations

13.

Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024. 741 indexed citations breakdown →

14.

Wang, Wenjun, Si-Pei Wu, Minzhang Guo, & Jianxing He. (2016). LMO4 is a prognostic marker involved in cell migration and invasion in non-small-cell lung cancer. Journal of Thoracic Disease. 8(12). 3682–3690. 16 indexed citations

15.

Dong, Zhong‐Yi, Si-Pei Wu, Ri-Qiang Liao, Shu‐Mei Huang, & Yi‐Long Wu. (2016). Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumor Biology. 37(4). 4251–4261. 75 indexed citations

16.

Wang, Wenjun, Si-Pei Wu, Yongsheng Shi, et al.. (2015). c‐MYB regulates cell growth and DNA damage repair through modulating MiR‐143. FEBS Letters. 589(5). 555–564. 22 indexed citations

17.

Dai, Zhenhua, et al.. (2014). Suppression of Allograft Rejection By a Novel Protein ESAT-6.. Transplantation. 98. 392–392. 1 indexed citations

18.

Chen, Weiguo, Si-Pei Wu, Gong Zhang, Wenjun Wang, & Yongsheng Shi. (2013). Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma. Oncology Letters. 6(5). 1234–1240. 23 indexed citations

19.

Yang, Xinglong, Gong Zhang, Si-Pei Wu, et al.. (2013). Nuclear β-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. Journal of Translational Medicine. 11(1). 114–114. 66 indexed citations

20.

Wang, Wenjun, Si-Pei Wu, Jiabin Liu, et al.. (2012). MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells. Cancer Research. 73(3). 1219–1231. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact